Drugging p53 mutants: Recent advances using small-molecule modulation strategies.

doi:10.1016/j.ejmech.2026.119149

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Drugging p53 mutants: Recent advances using small-molecule modulation strategies.

European journal of medicinal chemistry - 15 Nov 2026

Lopes Elizabeth A, Monteiro Tomás G, Santos Maria M M

Abstract excerpt

TP53 is the most frequently mutated gene in human cancers, with hundreds of mutations leading to loss of p53 tumor-suppressive functions. p53 mutations are closely associated with tumor progression, metastasis, and therapy resistance. In recent years, significant progress has been made in developing small-molecules targeting mutant (mut) p53 to restore its tumor suppressor activity. This review presents a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to TP53 gene
Share to Molecular Structure
Share to Mutation
Share to Neoplasms
Share to Small Molecule Libraries
Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 42468338
DOI: 10.1016/j.ejmech.2026.119149

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics